Heart failureHormonesNatural productsSubstrate metabolismSynthetic drugsHeart failure (HF) is a global public health problem with high morbidity and mortality. A large number of studies have shown that HF is ca
Acute heart failure (AHF) is a major burden disease, with a complex physiopathology, unsatisfactory diagnosis, treatment and a very poor prognosis. In the last two decades, a number of drugs have progressed from preclinical to early and late clinical development, but only a few of them have ...
fast, pounding, or irregular heartbeat or pulse increased sensitivity of the eyes to light lack or loss of strength nausea sleepiness or unusual drowsiness vomiting Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body...
Intermittent IV: Adolescents 500 or 1,000 mg infused at 50 mg/minute; a repeat dose of 500 mg may be administered if pain relief not observed (Reiter 2005; Sheridan 2015); dosing based on two retrospective reports that evaluated experience in 43 patients treated for acute migraine attack(s)...
Failure to disclose drug use could lead to the denial of a claim in the future, as insurers may use it as grounds for contestability. How to Improve Your Chances of Getting Approved To improve your chances of getting approved for life insurance as a drug user, consider the following: Mainta...
Furthermore, new experimental strategies that guide the medicinal chemistry re-engineering of drugs could improve repurposing efforts by tailoring a medicine to its new indication. In this Review, we summarize the historical approach to repurposing and discuss the technological advances that have created...
mutant TTR proteins, formulated as a lipid nanoparticle (LNP). A pivotal trial evaluating the safety and efficacy of ONPATTRO® demonstrated its ability to reduce efficiently and rapidly TTR protein levels in patients and improve significantly the neurological manifestations of the disease as well ...
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol . Lancet 2002 ; 359 : 995 – 1003 . II Article PubMed Google Scholar Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving...
DMDs have a blood pressure lowering effect; SGLT2i through their function in the kidney and GLP-1 RAs probably through reduction in body weight. GLP-1 RAs may also improve liver function tests. Most importantly, DMDs exert robust beneficial effects on the kidney and on the heart as a ...
presenting symptom. Chronic heart disease and diabetes are common co-morbidities in hospitalised COVID-19 patients, and research so far has shown that these patients are at higher risk of adverse clinical outcomes. A considerable...